INNPF (InnoCan Pharma) ROCE %: -36.10% (As of Mar. 2026)

What is InnoCan Pharma ROCE %?

InnoCan Pharma INNPF -10.53% 56 ROCE % is -36.10% as of Mar. 2026. GuruFocus rates INNPF with a GF Score™ of 56/100 and a GF Value™ of $10.03 (Possible Value Trap). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InnoCan Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -36.10%.

InnoCan Pharma (OTCPK:INNPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InnoCan Pharma ROCE % Related Terms

InnoCan Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma ROCE % Chart

InnoCan Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-372.91

-50.94

-75.81

16.22

1.09

InnoCan Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															1.89	-5.16	-60.01	73.71	-36.10

56GF Score

InnoCan Pharma Corp INNPF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InnoCan Pharma ROCE % Calculation

InnoCan Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	0.088	/	( ( (9.26 - 2.238)	+	(10.522 - 1.355) )	/ 2 )
	=	0.088	/	( (7.022	+	9.167)	/ 2 )
	=	0.088	/	8.0945
	=	1.09 %

InnoCan Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-3.26	/	( ( (10.522 - 1.355)	+	(10.845 - 1.952) )	/ 2 )
	=	-3.26	/	( ( 9.167	+	8.893 )	/ 2 )
	=	-3.26	/	9.03
	=	-36.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -36.10% mean?

InnoCan Pharma (INNPF) has a ROCE % of -36.10% as of Mar. 2026.

Is InnoCan Pharma's ROCE % too high?

InnoCan Pharma's current ROCE % is -36.10%. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does InnoCan Pharma's ROCE % compare to PG and CL?

InnoCan Pharma's ROCE % of -36.10% can be compared against companies in the Consumer Packaged Goods industry. The industry median ROCE % is 8.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Consumer Packaged Goods company?

The median ROCE % among Consumer Packaged Goods companies is 8.74, based on 1,936 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median ROCE % is 8.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current ROCE % is -36.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is InnoCan Pharma stock overvalued right now?

Based on GuruFocus' analysis, InnoCan Pharma (INNPF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.03, compared to a current price of $1.70 — trading 83.1% below its estimated fair value. The current ROCE % is -36.10%. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For InnoCan Pharma (INNPF), the current ROCE % is -36.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (INNPF) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of $1.70 is trading 83.1% below its estimated GF Value™ of $10.03. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for INNPF:

ROCE %: -36.10%
GF Value™: $10.03 vs. price of $1.70 (83.1% below fair value)
GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the INNPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies XCNQ:CGII XCNQ:ZRO PG XPAR:OR LSE:ULVR CL BOM:500696 LSE:RKT KVUE KMB XTER:HEN3 EL CHD OSTO:ESSITY B XTER:BEI TSE:4452 CLX BOM:531642 BOM:532424 XMAD:PUIG

Other Exchanges IP40:Germany INNO:Canada

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7

Website https://www.innocanpharma.com

InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.

56GF Score

Get the complete analysis for INNPF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.70

Price

$10.03

GF Value

View INNPF Analysis

See ROCE % data for all stocks →